Takeaway
- The results of this network meta-analysis suggest that the best choice for first-line advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab.
- Regorafenib and cabozantinib are best in refractory disease.
Why this matters
- The results suggest that these options should be the standard of care in the respective settings.Â
Study design
- Network...